INPP4B and breast carcinoma: However, INPP4B overexpressing ER+ breast cancer cells were more sensitive than control cells to pyrvinium, an FDA-approved drug that suppresses Wnt/β-catenin signaling, and to 4-OHT-pyrvinium combination treatment.